Guggenheim Maintains Neutral on Amgen, Raises Price Target to $343

Benzinga Newsdesk www.benzinga.com Positive 60.2%

Neg 0% Neu 0% Pos 60.2%

Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $340 to $343.